Hypokalemia associated with topical administration of dorzolamide 2% ophthalmic solution in cats.

  title={Hypokalemia associated with topical administration of dorzolamide 2\% ophthalmic solution in cats.},
  author={Tara M Czepiel and Neal T. Wasserman},
  journal={Veterinary ophthalmology},
OBJECTIVE To evaluate the effect of dorzolamide 2% ophthalmic solution on serum potassium and other hematologic parameters in cats. MATERIALS AND METHODS Part I: Medical records from a single institution were retrospectively reviewed. Inclusion criteria consisted of cats diagnosed with glaucoma for which appropriate clinicopathological data were available both prior to and after the initiation of therapy with dorzolamide 2% ophthalmic solution. Part II: Healthy adult cats were enrolled in a… 
The glaucomas in dogs
The clinical signs, diagnosis and medical treatment of glaucomas in dogs, a group of diseases commonly defined by an increased intraocular pressure which interferes with normal function of the optic nerve and retina, are described.


Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
Dorzolamide (dorzolamide hydrochloride), the first topical carbonic anhydrase (CA) inhibitor to become available for clinical use, lowers intraocular pressure (IOP) by reducing aqueous humour
Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat
Clinical and biochemical abnormalities resolved with short-term supportive care, potassium supplementation, and discontinuation of dorzolamide therapy, the first report of hypokalemia and metabolic acidosis associated with topical CAI therapy in a cat.
Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor.
  • T. MarenC. W. ConroyG. WynnsN. Levy
  • Biology, Medicine
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 1997
There is a clear pharmacological basis for the lack of any physiological effects of ocular dorzolamide, except on the eye itself, as seen following acetazolamide or methazlamide.
Clinical Pharmacokinetics of Dorzolamide
The pharmacokinetic and pharmacodynamic properties of dorzolamide and its metabolite in eye tissues and in the systemic circulation are summarized and the inhibition of carbonic anhydrase in red blood cells is moderate in the course of a topical treatment, avoiding systemic adverse effects.
Carbonic anhydrase inhibitor side effects. Serum chemical analysis.
Patients with chronic glaucoma complained of a symptom-complex of malaise, fatigue, weight loss, depression, anorexia, and loss of libido, which has found most commonly to threaten continuation of therapy.
Some physiological and biochemical effects of acetazolamide in the dog
The non-respiratory acidosis produced by acetazolamide makes it a useful model to enable the investigation of therapeutic regimes for treating acidosis of this type.
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function
An unusual case of fatigue, metabolic acidosis, and normocytic anaemia associated with ocular administration of the CAI, dorzolamide, in a patient with impaired renal function is reported.
Potassium supplements during treatment of glaucoma with acetazolamide.
Inappropriate renin secretion unmasked by captopril in hypertension of chronic renal failure is revealed.